Interpace Biosciences Aims for Nasdaq Uplisting
Interpace Biosciences, Inc. (OTCQX: IDXG) has recently announced a proactive move to strengthen its position in the stock market. The company is restructuring its preferred stock as a strategic first step toward seeking an uplisting of its common stock to Nasdaq. This initiative is facilitated through an agreement with its Series B Preferred Stock investors, which aims to catalyze growth and expand its investor base.
Restructuring of Preferred Stock
The company’s Series B Preferred Stock holders, Ampersand Capital Partners and 1315 Capital, have recently exchanged their existing shares for newly issued Series C Preferred Stock. This swap involves 47,000 shares being exchanged, paving the way for potential growth in equity and investor interest. Notably, the Series C shares have a conversion price set at $2.02, allowing for a straightforward transition into common stock as the company progresses.
Changes in Shareholder Rights
While these new shares come with certain advantages, the Series C Preferred Stock does not hold specific rights that were available to the Series B stock. This includes the removal of rights tied to liquidation preferences and voting controls, which gives the company greater flexibility in navigating its financial structure. The automatic conversion into common stock is contingent upon successfully achieving a Nasdaq uplisting.
Comments from Leadership
Tom Burnell, the Chairman, President, and CEO of Interpace, expressed gratitude towards Ampersand and 1315 Capital for their partnership. He emphasized the importance of this collaboration, stating, "The company has consistently looked for ways to optimize its capital structure to raise growth capital. The shared commitment between us and our investors for the long-term benefit of our shareholders, and significantly for the patients we serve, is invaluable. Molecular diagnostics plays a crucial role in the medical community, especially in stratifying risks for patients with thyroid and pancreatic cancers."
Pathway to Nasdaq
This exchange marks a significant milestone for Interpace as it seeks to fulfill Nasdaq's listing requirements, which encompass meeting certain equity and minimum bid price criteria. A successful uplisting is expected to provide Interpace with enhanced capital-raising capabilities, attracting more investors and increasing trading volumes for the common stock. The company's management believes that this strategic move will underlie their growth aspirations and facilitate potential acquisitions in the future.
About Interpace Biosciences
Interpace Biosciences is committed to advancing personalized medicine, providing valuable services that span the therapeutic value chain. This encompasses early diagnosis, prognostic planning, and the development of targeted therapeutic applications. The company excels in offering clinically relevant molecular diagnostic tests and comprehensive pathology services that assess cancer risk, using cutting-edge technology to enhance patient care and outcomes.
Innovative Molecular Diagnostic Tests
Currently, Interpace offers five commercialized molecular tests and is actively developing a test in a clinical evaluation program. Among these, PancraGEN® assists in diagnosing pancreatic cancer, while PanDNA® serves as a molecular-only version providing critical insights for physicians. Additionally, ThyGeNEXT® and ThyraMIR® v2 work together to diagnose thyroid cancers with accuracy, utilizing innovative sequencing and microRNA profiling techniques. Furthermore, RespriDX® differentiates between primary and metastatic lung cancers, contributing significantly to patient management strategies.
Future Developments and Community Engagement
The BarreGEN® assay is also in clinical evaluation, helping to assess the progression risk of Barrett’s Esophagus to esophageal cancer. This research involves gathering feedback from physicians to reinforce the clinical evidence supporting this important test. Interpace’s commitment to advancing molecular diagnostics underscores its role in the medical field, aiming to enhance patient care and outcomes across various cancer types.
Frequently Asked Questions
What is the purpose of the recent exchange of preferred stock?
The exchange aims to facilitate Interpace Biosciences' efforts to uplist its common stock to Nasdaq, strengthening its capital structure.
What types of molecular diagnostics does Interpace offer?
Interpace offers diagnostics for cancers, including pancreatic and thyroid cancers, along with tests that stratify patient risks.
Who are the investors involved in this stock exchange?
Ampersand Capital Partners and 1315 Capital are the investors involved in the preferred stock exchange.
How does uplisting to Nasdaq benefit Interpace?
A Nasdaq uplisting is expected to enhance visibility, attract more investors, and increase trading volumes, aiding in capital-raising efforts.
What future developments can we expect from Interpace?
Interpace is focused on expanding its molecular diagnostic offerings and advancing its clinical evaluations to improve patient care further.
